{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-108762","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2023-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.464718+00:00","generated_at":"2026-06-10T00:40:37.810154+00:00","sec_items":["1.01","2.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Edesa Biotech secures C$23M Canadian govt funding for EB05 Phase 3 ARDS study; CEO provides $10M credit facility","bullets":["Government of Canada commits up to C$23M (US$17M) for Phase 3 study of EB05 (paridiprubart) in ARDS; C$5.75M non-repayable.","Remaining C$17.25M conditionally repayable starting 2029 based on revenue growth; max repayment 1.4x principal.","CEO Dr. Par Nijhawan provides $10M revolving credit facility, $3.5M immediate availability, at CIBC US Base Rate + 300bps, due March 31, 2026.","Project must be completed by Dec 31, 2025, exclusively in Canada; includes regulatory submissions and manufacturing scale-up.","Credit facility is a related-party transaction; borrowing base includes grant reimbursement and license fee receivables."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-108762","json":"https://secwatch.observer/filing/0001104659-23-108762.json","markdown":"https://secwatch.observer/filing/0001104659-23-108762.md","text":"https://secwatch.observer/filing/0001104659-23-108762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000110465923108762/0001104659-23-108762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000110465923108762/tm2328265d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T00:40:37.810154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eeb377d6a449ec9db4658c1a617b532e1f32eec7","claim":"Edesa Biotech, Inc. entered into Multi-Year Contribution Agreement with Government of Canada valued at up to CAD $23 million ($17 million USD) (effective 2023-10-12).","evidence_excerpt":"On October 12, 2023, Edesa Biotech Research, Inc. (“Edesa Biotech Research”), a wholly owned subsidiary of Edesa Biotech, Inc. (the “Company”) and the Company, as guarantor, entered into a multi-year contribution agreement (the “Agreement”) with the Government of Canada.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000110465923108762/0001104659-23-108762-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Government of Canada"},{"label":"Value","value":"up to CAD $23 million ($17 million USD)"},{"label":"Effective","value":"2023-10-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}